Researcher Accuses AstraZeneca PLC Of Manipulating Brilinta Data
Published: Feb 04, 2014
In July 2011, the Food and Drug Administration approved AstraZeneca AZN.LN -0.46% PLC's anticlotting drug Brilinta for patients with certain severe coronary conditions. A study had shown the pill saved lives and reduced heart attacks—a real eye-opener in medicine. But behind the scenes, a drama is unfolding over whether the drug should have been approved.
Help employers find you! Check out all the jobs and post your resume.